Ganirelix
An FDA-approved GnRH antagonist decapeptide supplied as a ready-to-use prefilled syringe, injected daily during IVF stimulation to prevent a premature LH surge — the first GnRH antagonist approved in the United States.
Ganirelix is a daily injection used during IVF to stop your body ovulating before the eggs can be collected. It comes ready to use in a prefilled syringe, works within hours, and is typically given for only the last five or six days of stimulation. Compared with the older month-long protocols it gives about the same chance of a live birth with less risk of ovarian hyperstimulation syndrome.
What is Ganirelix?
Ganirelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist given once daily during IVF and ICSI stimulation to stop the pituitary from releasing a luteinizing hormone (LH) surge before the eggs can be collected. It is natural GnRH with substitutions at positions 1, 2, 3, 6, 8 and 10 — more extensively modified than cetrorelix, with two unusual diethyl-homoarginine residues that give the molecule its name and much of its receptor affinity. Approved by FDA in July 1999 as Antagon, it was the first GnRH antagonist to reach the US market, thirteen months ahead of cetrorelix. The brand name was dropped and the drug is now sold in the United States simply as ganirelix acetate injection, as Orgalutran in Europe and as Fyremadel in several markets, with a growing set of generics. Its practical signature is the presentation: a colourless, ready-to-use, aqueous solution in a single-dose prefilled syringe, with nothing to reconstitute.
What Ganirelix Is Investigated For
Ganirelix has one approved indication — inhibiting premature LH surges in women undergoing controlled ovarian hyperstimulation — and an unusually instructive dose-finding history behind it. The 1998 Ganirelix Dose-Finding Study Group trial randomized 333 women across six doses from 0.0625 mg to 2.0 mg, and found that more suppression is emphatically not better: LH escape fell as dose rose (16% of women at 0.0625 mg, 1.4% at 0.25 mg), but implantation rate collapsed at the top of the range, from 21.9% at 0.25 mg to 1.5% at 2 mg, with early miscarriage rates of 11.9% and 13% in the 1 mg and 2 mg arms against 0-3.7% elsewhere. The highest and lowest arms were stopped early by an independent committee, and 0.25 mg became the approved dose on the strength of a clear efficacy-and-outcome optimum rather than maximum suppression. The pivotal North American phase 3 trial (Fluker 2001, n=313) then compared ganirelix against a long leuprolide protocol and found comparable fertilization rates, slightly fewer oocytes retrieved (11.6 vs 14.1), nominally lower ongoing pregnancy (30.8% vs 36.4%), and markedly fewer moderate injection-site reactions (11.9% vs 24.4%). At class level, the 2016 Cochrane review of 73 RCTs in 12,212 women and the 2025 Cochrane network meta-analysis of 338 trials in 59,086 women both conclude that antagonist protocols match agonist protocols on live birth while reducing OHSS. Everything else — intrauterine insemination, PCOS ovulation induction, oocyte donation cycles — is studied but off-label.
History & Discovery
Ganirelix — developed as Org 37462 at Organon in the Netherlands — belongs to the third generation of GnRH antagonists, the generation that finally made the class usable. The first- and second-generation antagonists had the right pharmacology and the wrong side effect: they released histamine from mast cells in a dose-dependent way, producing systemic allergic reactions that stopped development repeatedly through the 1970s and 1980s. The third generation, ganirelix and cetrorelix among them, kept high receptor affinity while cutting histamine release enough that short courses were tolerable. An early human study in 1995 was explicitly framed around that property, reporting suppression of follicular-phase pituitary-gonadal function with a 'potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties.' The most interesting part of ganirelix's development is the dose-finding study published in 1998, because it produced a result that runs against the intuition of the whole field. Six doses were tested in 333 women, from 0.0625 mg to 2.0 mg. Pituitary suppression behaved exactly as expected — the higher the dose, the lower the LH, the lower the estradiol. Reproductive outcomes did not. Implantation rate peaked at 0.25 mg (21.9%) and fell to 1.5% at 2 mg; early miscarriage rose to 11.9% and 13% in the top two dose groups while sitting between zero and 3.7% in the others. The lowest and highest arms were terminated early on the advice of an external independent advisory committee. The reading has been debated ever since — whether the harm comes from estradiol deprivation, from direct effects on the endometrium or the oocyte, or from something else — but the practical conclusion was unambiguous, and 0.25 mg has been the dose ever since. It remains one of the clearest published demonstrations in reproductive medicine that the dose which best achieves a drug's mechanistic goal is not necessarily the dose that produces the best clinical outcome. FDA approved ganirelix acetate on 29 July 1999 under NDA 021057 to Organon, originally branded Antagon in the United States — the first GnRH antagonist approved in the country, ahead of cetrorelix in August 2000. The Antagon name was subsequently retired in the US, where the product is sold simply as ganirelix acetate injection; it is marketed as Orgalutran in Europe and as Fyremadel in several markets. The pivotal North American trial, published by the Ganirelix Study Group in 2001, compared the drug against a long leuprolide protocol in 313 women and established the profile that has defined antagonist protocols since: fewer injections, a shorter cycle, fewer and milder injection-site reactions, slightly fewer oocytes, and comparable pregnancy outcomes. Ganirelix came off patent in the early 2020s, and a wave of generics followed — Amphastar and Meitheal in 2022, Gland in 2023, Lupin later that year, Qilu in 2025 — which, with the parallel generics of cetrorelix, has substantially reduced the cost of the antagonist phase of an IVF cycle.
How It Works
The hypothalamus releases GnRH in pulses to tell the pituitary to make LH and FSH. Ganirelix is a redesigned version of GnRH that binds the same receptor without switching it on, blocking the natural hormone out. Because it simply occupies the receptor, LH falls within hours and recovers as soon as the drug clears. During IVF that stops the body from releasing the LH surge that would ovulate the eggs too early, without the weeks of pituitary shutdown that older drugs required.
Ganirelix acetate is a synthetic decapeptide (N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N9,N10-diethyl-D-homoarginyl-L-leucyl-N9,N10-diethyl-L-homoarginyl-L-prolyl-D-alanylamide, molecular weight 1570.4 as the anhydrous free base) derived from native GnRH by substitution at positions 1, 2, 3, 6, 8 and 10. The two N9,N10-diethyl-homoarginine residues at positions 6 and 8 are the structural signature of the molecule and contribute both to receptor affinity and to the reduced histamine-releasing profile that made the third-generation antagonists clinically usable. Ganirelix binds the pituitary GnRH receptor competitively and reversibly, preventing endogenous GnRH from triggering Gq/11-coupled signaling and gonadotropin release. The effect on LH is dose-proportional and rapid — within hours — with no desensitization phase and therefore no flare, and recovery of pituitary responsiveness follows clearance. Dose-proportionality and multiple-dose gonadotropin suppression were characterized in dedicated pharmacokinetic and pharmacodynamic studies before phase 3. The counterintuitive feature of the molecule is that maximal pituitary suppression is not the therapeutic goal: suppressing LH harder also suppresses follicular estradiol and, in the dose-finding program, collapsed implantation rates, which is why the approved dose sits at the inflection point rather than at the top of the dose-response curve.
Evidence Snapshot
Human Clinical Evidence
Extensive. FDA-approved since July 1999 on the basis of a six-arm dose-finding study in 333 women and phase 3 trials including the 313-woman North American Ganirelix Study Group comparison against leuprolide. Supplemented by trials in Chinese and Korean populations, obstetric and neonatal follow-up of antagonist-cycle pregnancies, large pharmacovigilance analyses, and the Cochrane reviews covering the antagonist class.
Animal / Preclinical
Comprehensive and largely historical. GnRH receptor antagonism, gonadotropin suppression, and the histamine-release properties that constrained earlier antagonist generations were characterized in rodent and primate models through the early 1990s.
Mechanistic Rationale
Very strong. Competitive, reversible blockade of a well-characterized G-protein-coupled receptor with an immediate and dose-dependent effect on gonadotropin release. The one mechanistic subtlety — that excessive suppression harms implantation — is itself well documented from the dose-finding data.
Research Gaps & Open Questions
What the current literature has not yet settled about Ganirelix:
- 01Why high-dose ganirelix damaged implantation and raised early miscarriage in the dose-finding study — whether the mechanism is estradiol deprivation, a direct endometrial effect, an effect on oocyte quality, or something else entirely. The observation set the approved dose but was never mechanistically resolved.
- 02Whether ganirelix and cetrorelix differ in any outcome that matters; after more than 25 years of parallel use there is still no randomized head-to-head trial, only retrospective single-centre comparisons.
- 03Whether the modestly lower oocyte yield of antagonist protocols affects cumulative live birth across all fresh and frozen transfers from one stimulation, rather than the single-cycle outcomes most trials report.
- 04How antagonist protocols compare with progestin-primed ovarian stimulation in freeze-all cycles, where the oral alternative removes the injection burden entirely and the main historical objection to progestins does not apply.
- 05Whether the flexible and fixed start protocols differ in outcome for specific responder phenotypes, which network meta-analysis has so far been unable to resolve.
- 06Long-term health outcomes in children conceived in antagonist cycles, beyond the obstetric and neonatal follow-up collected around the original approval.
Forms & Administration
Subcutaneous injection only, supplied as a colourless sterile aqueous solution in a single-dose prefilled syringe containing 250 mcg in 0.5 mL, alongside glacial acetic acid, mannitol and water for injection at approximately pH 5.0. No reconstitution is required and the syringe is used as supplied; air bubbles in the barrel are expected and do not need to be removed. The usual injection sites are the abdomen around the navel or the upper thigh, with the site swabbed and rotated between doses. Patients are routinely taught to self-administer after instruction. The needle shield has historically contained dry natural rubber, so latex-sensitive patients should confirm the composition of the specific product dispensed. All injectable peptides should be administered under the guidance of a qualified healthcare provider — for ganirelix, that means inside a monitored stimulation cycle.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
250 mcg (0.25 mg) per subcutaneous injection, supplied ready to use in a 0.5 mL prefilled syringe. This is the only approved dose, and the dose-finding data argue strongly against exceeding it.
Frequency
Once daily during the mid-to-late follicular phase. FSH stimulation is started on cycle day 2 or 3; ganirelix is added during the middle of the stimulation — commonly on day 5 or 6 in the fixed protocol, or when the leading follicle reaches roughly 14 mm in the flexible protocol — and continued daily up to and including the day the hCG trigger is given. Typical exposure is five or six injections.
Timing Considerations
Time of day
A consistent time each day, so the dosing interval stays close to 24 hours
Relative to meals
No relationship to food
Relative to exercise
Not tied to exercise timing.
Begun partway through stimulation — fixed day 5 or 6, or flexibly at a leading follicle of about 14 mm — and continued through the day of the trigger.
Cycle Length
One stimulation cycle. Ganirelix is not cycled, taken continuously, or used outside an active monitored stimulation.
Protocol Notes
The prefilled syringe is the practical advantage over cetrorelix: nothing to reconstitute, no mixing step, no transfer between needles. Air bubbles visible in the barrel are expected and should be left alone rather than expelled, since doing so can cost part of the dose. Injection is subcutaneous into the abdomen around the navel or the upper thigh, with sites rotated between doses and swabbed beforehand. A consistent daily time matters more than which time. Suppression is competitive and concentration-dependent, so letting the interval stretch much beyond 24 hours raises the chance of an LH rise before the next dose. Clinics usually specify a fixed time and ask to be told about any missed or late dose rather than having doses doubled up. Fixed-start and flexible-start protocols are both in routine use and neither has been shown to be clearly superior in network meta-analysis. A fixed day-5 or day-6 start is what the label describes and is simpler to run; a flexible start keyed to follicle size can save an injection or two but demands tighter monitoring, and a comparison of day-5 versus day-6 starts found that the timing of the start does influence the pattern of LH rises. One feature of the antagonist protocol is only available because the pituitary has not been desensitized: the trigger can be a GnRH agonist instead of hCG. In a high responder this substitutes a short endogenous LH surge for the long-acting hCG stimulus and substantially reduces OHSS risk, usually paired with freezing all embryos. That option simply does not exist in a long agonist cycle, and it is one of the strongest practical arguments for antagonist protocols in women at risk.
Ganirelix is approved only for inhibiting premature LH surges in women undergoing controlled ovarian hyperstimulation, within a monitored assisted-reproduction cycle. It has no standalone or wellness use.
Timeline of Effects
Onset
Within hours of the first injection. LH falls rapidly and dose-proportionally, with FSH following, and there is no flare or transient stimulatory phase at any point. This immediacy is why ganirelix can be introduced in the middle of a stimulation that is already underway rather than weeks before it starts.
Peak Effect
Suppression holds for as long as daily dosing continues, which is typically five or six days. It is reliable but not absolute — a minority of cycles still show an LH rise, which is why LH and progesterone are monitored through the antagonist phase rather than assumed to be controlled.
After Discontinuation
Fast and complete. Because the mechanism is competitive occupancy rather than receptor desensitization, pituitary responsiveness returns as the drug clears, over days rather than the weeks needed after an agonist depot. Dosing is stopped at the trigger precisely so the axis is free to respond — and it is this rapid recovery that makes a GnRH-agonist trigger possible in an antagonist cycle.
Monitoring & Measurement
Bloodwork & Labs
- •Serum LH through the antagonist phase — a rise above roughly 10 IU/L indicates escape from suppression
- •Serum estradiol, which tracks follicular response and drives the OHSS risk assessment
- •Serum progesterone before the trigger, to detect premature luteinization
- •Baseline anti-Mullerian hormone and antral follicle count, which predict response and inform protocol choice
Functional & Performance Tests
- •Serial transvaginal ultrasound for follicle count and diameter — sets the trigger timing and, in the flexible protocol, the ganirelix start
- •Endometrial thickness and pattern
- •Pre-trigger assessment of total follicle burden, which determines whether to give hCG, substitute a GnRH-agonist trigger, or cancel
When to Test
AMH and antral follicle count before the cycle; estradiol and ultrasound from the start of stimulation, intensifying as follicles grow; LH and progesterone through the antagonist phase; a final assessment on the intended trigger day.
Interpretation & Notes
This is clinic monitoring, not self-monitoring, and ganirelix only makes sense inside it. The pattern worth understanding as a patient is the OHSS pattern: rapidly rising estradiol with a large number of mid-sized follicles. In an antagonist cycle that pattern has a specific and effective answer — swap the hCG trigger for a GnRH-agonist trigger and freeze all embryos — which is available precisely because ganirelix left the pituitary able to respond. An LH rise during the antagonist phase usually prompts a review of injection timing and technique before anything else. Monitoring costs are bundled into the cycle rather than billed separately; the real burden is the several early-morning visits for ultrasound and bloodwork across roughly two weeks, which is one reason the shorter antagonist protocol is preferred by many patients.
Common Questions
Why is the ganirelix dose 250 micrograms and not more?
Because the dose-finding trial showed that pushing the dose higher actively harmed outcomes. In the 1998 study of 333 women, raising the dose did what you would expect to LH — escape fell from 16% at 0.0625 mg to 1.4% at 0.25 mg — but it also crushed estradiol (1475 pg/mL at the lowest dose versus 430 pg/mL at 2 mg) and, with it, implantation: 21.9% at 0.25 mg against 1.5% at 2 mg. Early miscarriage rates were 11.9% and 13% in the 1 mg and 2 mg groups versus zero to 3.7% elsewhere. The 0.0625 mg and 2.0 mg arms were terminated early on the advice of an independent advisory committee. 0.25 mg is the point at which the LH surge is reliably prevented without over-suppressing the follicular environment the embryo has to implant into.
What is the difference between ganirelix and cetrorelix?
Chemically they are different decapeptides — ganirelix is substituted at six positions and carries two diethyl-homoarginine residues, cetrorelix at five with a D-citrulline at position 6 — but clinically they are near-interchangeable. Both are given at 0.25 mg subcutaneously once daily from the middle of stimulation to the trigger, and no randomized trial has established that either is better. The handling differs: ganirelix is a ready-to-use solution in a prefilled syringe, cetrorelix is a lyophilized powder requiring reconstitution. A 2025 single-centre retrospective cohort of 9,424 propensity-matched cycles found comparable live birth rates (49.4% ganirelix vs 47.2% cetrorelix, p = 0.074) with marginally better LH control on cetrorelix; those differences are small, retrospective, and from one clinic.
Does the ganirelix syringe contain latex?
Historically yes, and it still matters. The prefilled syringe presentation has carried dry natural rubber (a latex derivative) in the needle shield, and known hypersensitivity to that component is listed as a contraindication in the labelling alongside hypersensitivity to ganirelix itself and to GnRH or any GnRH analogue. Patients with a latex allergy should raise it with the clinic before the cycle starts, because components vary between the originator product and the several generics now on the market — this is a question to settle against the specific product being dispensed rather than from a general reference.
Will ganirelix reduce the number of eggs I get?
Slightly, on average, compared with a long agonist protocol — and this is consistent across the literature rather than a quirk of one trial. The pivotal North American trial retrieved a mean 11.6 oocytes on ganirelix versus 14.1 on leuprolide, and the 2025 Cochrane network meta-analysis estimates roughly one fewer oocyte in women with a predicted normal response. What has not been shown is any corresponding reduction in live birth: the 2016 Cochrane review found no conclusive difference (OR 1.02) and the 2025 network meta-analysis agreed (RR 0.95). Antagonist protocols also cancel more cycles for poor response and far fewer for OHSS risk, which is the trade most clinics now accept.
Is ganirelix on the WADA Prohibited List?
No. WADA prohibits GnRH and its agonist analogues for male athletes under class S2.2.1, naming buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin. Ganirelix is an antagonist — it blocks the receptor rather than stimulating it — and is not named on the 2026 or 2027 Prohibited Lists, nor are cetrorelix or degarelix. The rule tracks the pharmacology: an agonist can be misused to raise endogenous testosterone, while an antagonist suppresses it and would be counterproductive for an athlete. Status should still be confirmed with the relevant anti-doping organization, since List wording is reviewed every year.
Who Ganirelix Is NOT For
- •Known or suspected pregnancy — ganirelix is given before conception within a cycle and is contraindicated once pregnancy is established or suspected.
- •Known hypersensitivity to ganirelix acetate or to any component of the product, including the dry natural rubber (latex) historically present in the needle shield of the prefilled syringe.
- •Known hypersensitivity to GnRH itself or to any other GnRH analogue, agonist or antagonist.
- •Men and children — ganirelix has no approved use outside controlled ovarian hyperstimulation in adult women.
- •Use outside a monitored assisted-reproduction cycle, where ovarian response and OHSS risk cannot be assessed before the trigger decision.
- •Caution rather than absolute contraindication in women with a history of severe allergic conditions; hypersensitivity reactions including anaphylaxis have been reported, in some cases after the first dose.
Drug & Supplement Interactions
No clinically significant pharmacokinetic drug interactions have been established for ganirelix, and the short duration of exposure limits the opportunity for any. The meaningful interactions are pharmacodynamic and designed into the protocol. Ganirelix is given alongside gonadotropins — recombinant FSH, hMG or urinary FSH — and by suppressing endogenous LH it changes the hormonal environment those gonadotropins act in; the label notes that taking advantage of endogenous pituitary FSH early in the cycle may reduce the exogenous FSH requirement. Concurrent GnRH agonist use is pharmacologically self-defeating, since the two occupy the same receptor to opposite ends. The hCG trigger acts downstream at the LH receptor and is unaffected by GnRH receptor blockade. The interaction worth understanding is the positive one: because ganirelix does not desensitize the pituitary, a GnRH-agonist trigger can be substituted for hCG in women at high risk of OHSS, producing a short physiological LH surge instead of a prolonged hCG stimulus. Oral contraceptive pre-treatment, used for cycle scheduling, alters the baseline hormonal state rather than interacting with ganirelix directly, and progestin-primed stimulation is an alternative to ganirelix rather than a companion to it.
Safety Profile
Common Side Effects
Cautions
- • Contraindicated in known or suspected pregnancy
- • Contraindicated with known hypersensitivity to ganirelix acetate or any component, including the dry natural rubber (latex) historically present in the needle shield of the prefilled syringe
- • Contraindicated with known hypersensitivity to GnRH or any other GnRH analogue
- • Hypersensitivity reactions including anaphylaxis have been reported, in some cases with the first dose
- • Should only be used within a supervised assisted-reproduction cycle with ultrasound and hormone monitoring
- • Not for use in men or in children
- • Pharmacovigilance signals reported in FAERS and JADER data are dominated by events intrinsic to IVF — OHSS, miscarriage, ectopic pregnancy — and disproportionality statistics in this setting are strongly confounded by the indication rather than indicating drug-specific risk
What We Don't Know
The approved indication is thoroughly characterized through a structured dose-finding program, multiple phase 3 trials, more than 25 years of use, and repeated Cochrane synthesis. The real uncertainties lie elsewhere: whether the oocyte-yield difference versus agonist protocols affects cumulative live birth across all transfers from one stimulation, whether any patient subgroup genuinely does better on an agonist, and how antagonist protocols interact with progestin-primed stimulation and freeze-all strategies that postdate the pivotal comparisons. Long-term offspring outcomes beyond the original obstetric and neonatal follow-up remain thinly documented.
Legal Status
United States
FDA-approved prescription drug (ganirelix acetate injection, originally Antagon, NDA 021057, approved 29 July 1999 to Organon), with multiple generic products approved from 2022 onward. Indicated solely for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. Not a controlled substance. Dispensed through fertility clinics and specialty pharmacies as part of a monitored cycle; there is no legitimate consumer or wellness channel.
International
Approved for the same indication across the European Union, the United Kingdom, Canada, Japan, Australia and much of Asia and Latin America. Marketed as Orgalutran in Europe and as Fyremadel in several markets, with generics now widely available.
Sports & Competition
Not prohibited. WADA class S2.2.1, 'Testosterone-stimulating peptides in males,' covers GnRH (gonadorelin) and its agonist analogues, naming buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin. Ganirelix is a GnRH antagonist and is not named in that entry or elsewhere on the 2026 or 2027 Prohibited Lists; the same applies to cetrorelix and degarelix. The distinction reflects pharmacology rather than oversight — an antagonist suppresses endogenous testosterone and offers no performance rationale. Athletes should nonetheless confirm current status with their anti-doping organization, as List wording is reviewed annually.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
A higher ganirelix dose gives better pituitary suppression and therefore a better cycle.
Reality
It gives better suppression and a worse cycle. The dose-finding study found implantation rates of 21.9% at 0.25 mg and 1.5% at 2 mg, with early miscarriage rates of 11.9% and 13% in the top two dose arms, and the extremes were stopped early by an independent committee. The approved dose sits at the point where LH surges are prevented without over-suppressing the follicular environment the embryo has to implant into.
Myth
Ganirelix stimulates the ovaries or improves egg quality.
Reality
It suppresses. The ovarian stimulation comes from the FSH or hMG given alongside it; ganirelix exists only to stop a premature LH surge. If anything, antagonist protocols yield slightly fewer oocytes than long agonist protocols — 11.6 versus 14.1 in the pivotal trial — without a corresponding difference in live birth.
Myth
Ganirelix is interchangeable with a GnRH agonist like leuprolide.
Reality
They reach a similar endpoint by opposite mechanisms and on completely different schedules. An agonist must overstimulate the pituitary for one to two weeks before it desensitizes, so agonist protocols start weeks ahead; ganirelix blocks the receptor from the first dose and is given for five or six days in the middle of stimulation. The difference also determines which trigger options are available — a GnRH-agonist trigger is possible only in an antagonist cycle.
Myth
The air bubble in the prefilled syringe needs to be expelled before injecting.
Reality
The labelling states explicitly that air bubbles may be present in the prefilled syringe, that this is expected, and that removal is not needed. Attempting to expel the bubble risks expelling part of the 250 mcg dose, which is the opposite of helpful in a drug where dose precision demonstrably matters.
Myth
Ganirelix is banned in sport because it is a GnRH drug.
Reality
WADA S2.2.1 prohibits GnRH and its agonist analogues for male athletes, naming seven agonists. Ganirelix is an antagonist and appears nowhere on the 2026 or 2027 Prohibited Lists, alongside cetrorelix and degarelix. An antagonist suppresses rather than raises endogenous testosterone, which is why the rule is written the way it is.
Published Research
26 studiesReal-World Safety and Effectiveness of Ganirelix for Ovarian Stimulation in Chinese Women: A Multicenter, Prospective, Single-Arm, Observational Study
Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis
The 2025 Cochrane network meta-analysis of 338 studies and 59,086 women — the most current synthesis, and more conservative than its predecessor. Short antagonist protocols show little to no difference in live birth or ongoing pregnancy (RR 0.95), may reduce OHSS (RR 0.88), and may yield slightly fewer oocytes than long agonist protocols.
Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study
Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024)
Twenty years of FAERS and JADER reports — 1,096 and 62 cases respectively. The dominant signals are OHSS, injection-site pain, miscarriage and fetal death, with a median time to onset of 13 days. The enormous reporting odds ratio for OHSS (over 2,400) is an artefact of indication rather than a measure of risk: ganirelix is used almost exclusively in IVF, where OHSS is the characteristic complication of the cycle itself.
GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy
Ganirelix and the prevention of premature luteinizing hormone surges
Synthesis and characterization of two potential impurities (des-ethyl-Ganirelix) generated in the Ganirelix manufacturing process
What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis
Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study
Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial
A phase 4 equivalence trial pitting oral medroxyprogesterone acetate against ganirelix for pituitary suppression in oocyte donors — the clearest randomized test of the progestin-primed stimulation strategy that has emerged as an alternative to antagonists in freeze-all cycles, where the absence of a fresh transfer removes the objection to progestin exposure.
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology
The 2016 Cochrane review, 73 RCTs and 12,212 women. No conclusive difference in live birth between antagonist and long agonist protocols (OR 1.02, 95% CI 0.85-1.23) alongside a substantial reduction in ovarian hyperstimulation syndrome (OR 0.61, 95% CI 0.51-0.72) — the evidence base that moved antagonist protocols to first line.
Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation
A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates
Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples
Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial
Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization
Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome
Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix
The follow-up study of pregnancies and babies conceived in ganirelix cycles, carried out because the antagonist class was new and the question of offspring outcomes was genuinely open. It found obstetric and neonatal outcomes comparable to the agonist comparator — reassuring, though limited in size and length of follow-up, and still the main published source on this question.
The gonadotrophin-releasing hormone antagonist ganirelix - history and introductory data
Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotrophin-releasing hormone antagonist ganirelix (Orgalutran/Antagon)
Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation
The pivotal North American Ganirelix Study Group phase 3 trial (Fluker 2001, n=313) against a long leuprolide protocol. Fertilization rates were essentially identical (62.4% vs 61.9%), oocyte yield was lower on ganirelix (11.6 vs 14.1), ongoing pregnancy was nominally lower (30.8% vs 36.4%), and moderate injection-site reactions were halved (11.9% vs 24.4%) on a markedly shorter regimen.
Ganirelix (Drugs review of pharmacology, clinical efficacy and tolerability)
Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses
A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
The six-arm dose-finding trial in 333 women that set the approved dose and demonstrated that more pituitary suppression is worse, not better. LH escape fell with dose (16% at 0.0625 mg, 1.4% at 0.25 mg) but implantation collapsed at the high end (21.9% at 0.25 mg versus 1.5% at 2 mg), early miscarriage reached 11.9% and 13% in the 1 mg and 2 mg arms, and the extreme arms were halted early by an independent advisory committee.
Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)
Quick Facts
- Class
- GnRH Antagonist
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Oct 2026
- Citations
- 26PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.